Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451254 | 0.87 | GRM5 (0.35) | POLBCHRNB4CHRNA3IDO1TDO2 | |
| SCHEMBL1075073 | 0.86 | PTGS1 (0.35) | POLBIDO1TDO2NPC1MAPT | |
| SCHEMBL1073917 | 0.83 | KCNH2 (0.36) | POLBIDO1TDO2MAPT | |
| SCHEMBL1073004 | 0.81 | PDE4B (0.41) | IDO1TDO2CYP11B2 | |
| SCHEMBL2450914 | 0.81 | CYP11B1 (0.39) | CHRNB2CHRNA4CYP11B2NPC1MAPT | |
| SCHEMBL1074544 | 0.78 | KDM4E (0.35) | IDO1TDO2 | |
| SCHEMBL19953120 | 0.77 | USP2 (0.38) | IDO1TDO2 | |
| SCHEMBL2451435 | 0.76 | PIK3CA (0.34) | — | |
| SCHEMBL2342861 | 0.76 | MEN1 (0.35) | CHRNB2CHRNA4NPC1RAB9A | |
| SCHEMBL1074021 | 0.75 | PTGS1 (0.35) | POLBIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | claimed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | claimed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | claimed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | claimed |
| EP-2053044-A1 | Novel imidazole derivatives | Syngenta Participations AG (CH) | 2009-04-29 | — | — | EP | claimed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | claimed |
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| EP-2053044-A1 | Novel imidazole derivatives | Syngenta Participations AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | CBR3, C3AR1, C1R | POLB 4592/4885CHRNB4 1866/4885CHRNA3 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.